Butler University

Digital Commons @ Butler University
Scholarship and Professional Work – COPHS

College of Pharmacy & Health Sciences

2013

Vancomycin and Gentamicin Pharmacokinetic Alterations in an
Adolescent Amputee
Kristen R. Nichols
Butler University, knichols@butler.edu

Kari M. Edison
Michelle D. Rosenbaum
Chad A. Knoderer
Butler University, cknodere@butler.edu

Follow this and additional works at: https://digitalcommons.butler.edu/cophs_papers
Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Pediatrics Commons

Recommended Citation
Nichols, Kristen R.; Edison, Kari M.; Rosenbaum, Michelle D.; and Knoderer, Chad A., "Vancomycin and
Gentamicin Pharmacokinetic Alterations in an Adolescent Amputee" (2013). Scholarship and Professional
Work – COPHS. 69.
https://digitalcommons.butler.edu/cophs_papers/69

This Article is brought to you for free and open access by the College of Pharmacy & Health Sciences at Digital
Commons @ Butler University. It has been accepted for inclusion in Scholarship and Professional Work – COPHS
by an authorized administrator of Digital Commons @ Butler University. For more information, please contact
digitalscholarship@butler.edu.

JPPT
Case Report
Vancomycin and Gentamicin Pharmacokinetic Alterations in an
Adolescent Amputee
Kristen R. Nichols, PharmD,1,2,3 Kari M. Edison, PharmD,1 Michelle D. Rosenbaum, PharmD,1
and Chad A. Knoderer, PharmD1,2,3
Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University, Indianapolis,
Indiana, 2Department of Pharmacy, Riley Hospital for Children, Indiana University Health, Indianapolis, Indiana,
3
Department of Pediatrics, Ryan White Center for Pediatric Infectious Disease, Indiana University School of Medicine,
Indianapolis, Indiana
1

A 14-year-old male with bilateral above-the-knee amputations presented to our hospital for treatment of
a skin and soft-tissue infection. We report the experience of vancomycin and gentamicin therapy in this
patient. Because these medications require weight-based dosages and pharmacokinetic monitoring of
serum levels, it was necessary to obtain peak and trough levels of the two drugs in order to determine the
pharmacokinetic differences in this patient compared to those in an adolescent male without amputations.
To our knowledge, this is the first report describing pharmacokinetic differences in an adolescent amputee.
INDEX TERMS adolescent, amputee, gentamicin, pharmacokinetics, vancomycin
J Pediatr Pharmacol Ther 2013;18(1):63–66

INTRODUCTION
Vancomycin and aminoglycoside dosages in
children can be challenging because of developmental pharmacologic changes and pharmacokinetic differences observed in children compared
to those in adults.1 While generally uncommon,
pediatric amputees represent a population for
which, to our knowledge, no published reports
describe pharmacokinetic alterations or provide
specific dosing recommendations. We report
pharmacokinetic alterations observed with vancomycin and gentamicin in an adolescent amputee and discuss considerations for pharmacists.

CASE REPORT
A 14-year-old (46.4 kg, 135 cm) Caucasian male
presented to the hospital with redness, swelling,
and serosanguinous drainage from the second
digit on his left hand 3 days after sustaining an
injury. It was reported that swelling and redness
spread to the dorsal portion of the finger 2 days
after the incident. The patient has a medical history significant for attention deficit hyperactivity
disorder, bipolar disorder, congenital insensitivJ Pediatr Pharmacol Ther 2013 Vol. 18 No. 1 • www.jppt.org

ity to pain, and bilateral above-the- knee amputations (AKA; left lower extremity in 2006 and right
lower extremity in 2008) because of recurrent
lower extremity infections.
Upon hospital admission, vancomycin, 690 mg
(15 mg/kg/dose) intravenous (IV) every 8 hours;
clindamycin, 460 mg (10 mg/kg/dose) IV every 8
hours; and gentamicin, 140 mg (3 mg/kg/dose)
IV every 24 hours were empirically initiated for
activity against methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA,
respectively) infection and group A Streptococcus
spp infection. Blood and wound cultures were
obtained on the day of admission and prior to
antibacterial initiation. The wound culture subsequently grew MRSA and Streptococcus pyogenes,
while the blood culture revealed Streptococcus
pyogenes (susceptibility tests were not performed
secondary to the rare occurrence of antimicrobial
resistance in this organism). The vancomycin
minimum inhibitory concentration for the MRSA
was ≤0.5 mg/L. The patient’s serum creatinine
(SCr) concentration upon antibiotic initiation
was within the institution’s normal limits for the
patient’s age at 0.53 mg/dL.
Due to the amputation history and potential
63
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Table. Calculated Pharmacokinetic Parameters and Monitoring
Parameter

Vancomycin

Gentamicin

Dosage

690 mg every 8 hr

140 mg every 24 hr

mg/kg/dose

15 mg/kg/dose

3 mg/kg/dose

Dose at which concentrations were obtained

Fifth

Second

Peak serum concentration (corrected)

43.2 (49.2) mg/L

10.8 mg/L

Time to peak obtained in relation to dose

30 min after 2-hr infusion

1 hr after 30-min infusion

Trough serum concentration (corrected)

8.4 (10.2) mg/L

< 0.5 mg/L

Time to trough obtained in relation to dose

8 hr and 45 min after last dose

23 hr and 40 min after last dose

Rate of elimination (Ke)

0.262 hr

Vd (L/kg)

0.27 L/kg

0.28 L/kg

Elimination half-life

2.6 hr

*

−1

*

Ke, eliminate rate; Vd, volume of distribution
*Could not be accurately calculated as serum concentration values were below the lower limit of detectability.

for altered pharmacokinetic parameters, trough
and peak concentrations of both vancomycin and
gentamicin were obtained. It was suspected that
the patient might have had an altered volume
of distribution (Vd) for each drug and that his
SCr concentration might not have adequately
reflected drug clearance due to his limited mobility and lean adipose tissue. Concentrations
and calculated parameters are described in the
Table. Gentamicin pharmacokinetic parameters
could not be completely calculated due to the
reported trough concentration of less than 0.5
mg/L, which is the lower limit of detection at
our institution’s laboratory.
After final organism identification and susceptibility testing, gentamicin was discontinued. The
vancomycin dose was increased to 750 mg every
8 hours to target a goal trough serum concentration of 10 to 15 mg/L. The patient received a total
of 10 days of antibiotic therapy, including clindamycin monotherapy (450 mg IV every 6 hours)
for the final 3.5 hospital days. Blood cultures were
consistently negative after the original positive
culture on the day of admission.

DISCUSSION
Limited pharmacokinetic data available for the
amputee population makes drug dosages a significant challenge. Specifically, current literature
on vancomycin or aminoglycoside dosages in
pediatric amputees is not available. While there
are a small number of resources available for
determining body surface area and preamputa64

tion body weight in adults with lower limb amputations, there is currently no correlation to the
pediatric population.2,3 The 14-year-old patient
in this case report represented a unique dosage
challenge because of general pharmacokinetic
differences that can be observed in children and
adolescents in addition to potential distribution
volume alterations related to his amputations.
Actual body weight is used to calculate aminoglycoside doses for pediatric patients, unless
the patient weighs more than 125% of their
ideal body weight (IBW), in which case a dosing weight is recommended based on standard
adult practice.4 Actual body weight is also used
for vancomycin dosages.5 Our patient weighed
46.4 kg, reflecting a normal weight for a typical
14-year-old male. His amputation status made
calculation of his true IBW and ultimately drug
dosage difficult. Furthermore, a method for
determining the adjusted or dosage weight for
aminoglycosides in pediatric amputees is not
available. As pharmacists, it is imperative to
thoroughly review each patient’s medical records
for pertinent history and physical examination
findings and even to visualize each patient in
whom vancomycin or aminoglycosides is to be
administered. Important insights can be gained
by observing the patient.
Each of the drug serum concentrations were
obtained to determine drug clearance and volume of distribution and to determine whether
efficacy and safety concentration targets were
met. The gentamicin peak serum concentration
was higher than necessary for synergy (3 to 5
J Pediatr Pharmacol Ther 2013 Vol. 18 No. 1 • www.jppt.org
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mg/L is our institution standard).6 We posit
that the elevated concentration was caused by
a slightly decreased Vd value resulting from the
amputations, relative to those of normal pediatric levels.7 The true volume of distribution is
likely slightly lower than the calculated value
of 0.28 L/kg, as the serum concentration was
obtained 1 full hour (compared to 30 minutes)
following the end of a 30-minute infusion. The
“peak” serum concentration may also be higher
than expected because the patient was given a
3 mg/kg/dose based on his actual rather than
an adjusted weight. While renal dysfunction
would not be expected in an otherwise normal
adolescent with bilateral AKA, SCr level may not
be the most useful indication of renal function
because of decreased muscle mass and mobility.
The patient’s undetectable gentamicin trough
serum concentration suggested adequate renal
gentamicin clearance.
This patient’s therapy was initiated with 15
mg/kg of vancomycin every 8 hours, which is
an appropriate empirical dose for a 14-year-old
patient with normal renal function. The subsequent peak serum concentration was higher than
anticipated given the dose administered and was
most likely due to a calculated vancomycin Vd of
0.27 L/kg, which is lower than that expected for
an adolescent. Typical “normal” values originate
mostly from younger patients with a mean age
of 7 years.8 Reported pediatric vancomycin Vd
values range from 0.43 L/kg to 0.63 L/kg.8−10 It
is difficult to determine whether the low Vd value
in our patient was caused by normal variation
or was secondary to the amputation, and unfortunately, no values for adult amputees could be
found in the literature. Although the vancomycin
trough serum concentration was not drawn at
the correct time, the patient’s calculated true
trough serum concentration of 10.2 mg/L was
close to the recommended minimum value of 10
mg/L.11 However, to ensure a trough concentration within a target range of 10 to 15 mg/L, the
dose was increased. Further concentrations were
not obtained as it could be reasonably expected
that the change in dose would result in trough
concentration within the target range.
The cost of serum concentrations should be a
consideration when caring for unique patients.
At our institution, patients are charged approximately $150 for each serum concentration. While
peak vancomycin concentrations are generally
J Pediatr Pharmacol Ther 2013 Vol. 18 No. 1 • www.jppt.org

not advocated because of the lack of correlation
with efficacy, it was justified in this case in order
to determine patient-specific pharmacokinetic
parameters.11 A peak gentamicin concentration
was also obtained to determine pharmacokinetic parameters. In an otherwise healthy child,
neither the vancomycin nor the gentamicin peak
concentrations would have been obtained at our
institution. It was believed that the benefit of
using peak concentrations to calculate pharmacokinetic parameters in our adolescent amputee
outweighed the additional charge.

CONCLUSIONS
This case report is the first to describe serum
concentrations and pharmacokinetic alterations with vancomycin or aminoglycosides in
an adolescent amputee and offers a reminder
to pharmacists practicing with unique patient
populations. While population pharmacokinetic
data and medical guidelines aid in optimal vancomycin and gentamicin drug doses in a relatively
robust group of patients, those cannot replace the
evaluative process pharmacists must consistently
perform to adequately ensure optimal doses in
all populations. Pharmacists must work to find
a balance between evidence-based guidelines or
standards of care and the need to use serum drug
monitoring to optimize drug efficacy and safety.
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